Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors

摘要

A pharmaceutical combination comprising a topoisomerase I inhibitor, and an Hsp90 inhibitor according to the following formulae (I) (Ia) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein.;

主权项

1. A pharmaceutical composition comprising a topoisomerase I inhibitor and an Hsp90 inhibitor wherein the topoisomerase I inhibitor is Irinotecan, topotecan, camptothecin, 9-aminocamptothecin, GG-211, DX-8951f and SN-38; and wherein the Hsp90 inhibitor is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1,2,4]triazole, 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-2-isopropylphenyl dihydrogen phosphate, or a tautomer, or a pharmaceutically acceptable salt thereof.